Creating Next Generation ADCs with Industry-Leading DAR Precision, Plasma Stability & Tumor-Selective Linker Payload Activation
Time: 11:30 am
Details:
- Showcasing LCB’s novel next-generation site-specific ADC platform technology
- Demonstrating proprietary cancer-selective linker providing significantly improved therapeutic index
- Highlighting tumor-specific and ultra-potent DNA-damaging crosslinking payload with superior efficacy and reduced toxicity